Glenmark Life Sciences Limited IPO

Mainboard

Pharmaceuticals & Drugs

Listed On: Aug 6, 2021 at ₹ 750.0(NSE)

₹ 14400 /20 Shares

Check Allotment

Price Summary

Last Closing

1,149.60 (59.67%)

52 Week High

1,335.10

52 Week Low

611.20

Last Update

20-Sep-2024 3:30 PM

IPO Details

27 Jul, 2021

Open Date

29 Jul, 2021

Close Date

03 Aug, 2021

Allotment Date

06 Aug, 2021

Listing Date

Issue Price

₹695-720 per equity share

Face Value

₹2 Per Equity Share

Listing at Group

BSE, NSE

Registrar

KFintech Private Limited

List Price

750.0(NSE)

Listing Date

2021-08-06

Market Lot

20 Shares (₹14,400/-)

Lead Manager

BoA Merrill Lynch, BOB Capital Markets Limited, DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd), Goldman Sachs (India) Securities Private Limited, Kotak Mahindra Capital Company Limited, SBI Capital Markets Limited

Issue Size

1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares

Retail Portion

35%

Subscription

45.08 times

IPO Docs

DRHP RHP

IPO Subscription Details

As on	QIB	NII	Retail	Total
Shares Offered / Reserved	42,42,379	32,32,770	75,43,130	1,50,18,279
Day 1 - 27-07-20 05:00 PM	0.00 x	0.85	5.17 x	2.78 x
Day 2 - 28-07-20 05:00 PM	1.40 x	3.48	9.51 x	5.90 x
Day 3 - 29-07-20 05:00 PM	37.30 x	125.62	15.00 x	45.08 x

Total No. of Applications: 3950392 (Approx)

Retail Subscription on the basis of Applications: 10.74 times

Valuations

Earnings Per Share (EPS)

₹32.61/-

P/E Ratio

25.13

RoNW

46.71%

Net Asset Value (NAV) - As on 31.03.21

₹69.83

Company Financials All values are in ₹ Cr.

	31-Mar-21	31-Mar-20	31-Mar-19
Assets	1,997.07	1,725.60	1,475.39
Revenue	1,885.97	1,549.30	886.86
Profit After Tax	351.58	313.09	195.59

About The Company

Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

	P/B Ratio	P/E Ratio	RoNW	Net Worth
Glenmark Lifesciences Limited	10.31	25.13	46.71%	1,859.76
Divis Laboratories Limited	12.95	61.40	210%	7,031.96
Laurus Labs Limited	22.06	77.45	15.56%	4,835.86
Shilpa Medicare Limited	7.15	42.08	17.00%	931.27
Aarti Drugs Limited	5.12	287.45	1.78%	2,159.31
Solara Active Pharma Sciences Limited	6.85	46.59	14.69%	1,645.65

IPO - Ratings

Anand Rathi	Subscribe
Axis Capital	Neutral
Capital Market	May apply
Choice Equity Broking Pvt Ltd	Subscribe
GEPL Capital Ltd	Subscribe
HDFC Securities Limited	Neutral
ICICI Direct	Subscribe
Investmentz Ltd	Subscribe
SMC Global	May Apply
Sushil Finance Ltd	Subscribe
Ventura Securities Limited	Subscribe

- Promoter(s)

Pre Issue Share Holding: 100%

Post Issue Share Holding: 82.84%

Company Promoter(s)

Glenmark Pharmaceuticals Limited

IPO - Issue Objectives

To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
To finance capital expenditure requirements.
To meet general corporate purposes.

IPO - Anchor Investors

Glenmark Life Sciences mobilises Rs 454 crore from anchor investors ahead of IPO

HSBC Global Investment Funds, Government Pension Fund Global, Oaktree Emerging Markets Equity Fund LP, Copthall Mauritius Investment Ltd -ODI account, Societe Generale-ODI, Kuber India Fund and Reliance General Insurance Company are among the anchor investors.

IPO - FAQs

Ans. Glenmark Life Sciences Limited IPO is a Mainboard IPO. The issue is priced at ₹695-720 per equity share. The minimum order quantity is 20 Shares. The IPO opens on Jul 27, 2021, and closes on Jul 29, 2021. KFintech Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Glenmark Life Sciences Limited IPO opens on Jul 27, 2021 and closes on Jul 29, 2021.

Ans. The size of Glenmark Life Sciences Limited IPO is 1513.60 Crore; 1060 Crore Fresh Issue + 453.60 Crore Offer for Sale of 63,00,000 Shares.

Ans. The IPO price band is set between ₹695-720 per equity share.

Ans. To apply for Glenmark Life Sciences Limited IPO IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Glenmark Life Sciences Limited IPO in the List of IPOs
- Press "Apply" Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Glenmark Life Sciences Limited IPO is Aug 3, 2021.

Ans. The Glenmark Life Sciences Limited IPO will be listed on Aug 6, 2021.

Ans. Follow the steps to check the allotment status for Glenmark Life Sciences Limited IPO here.